|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 13, 2002; DOI 10.1182/blood-2002-02-0401.
IMMUNOBIOLOGY
From the Department of Immunology and Mayo Graduate
School, Mayo Clinic, Rochester, MN.
Many of the mechanisms that govern T-cell homeostasis remain
obscure. Here we report that repeated administration of synthetic oligodeoxynucleotides containing unmethylated cytosine-guanine motifs
(CpG-ODN) into mice induces a systemic antigen-independent expansion of
naive and memory T cells in a full T-cell compartment. Expansion of T
cells was observed on both CD4+ and CD8+ T-cell
subsets and was produced not by inducing the proliferation of the cells
but by preventing their death. The antiapoptotic effects of CpG-ODN on
T cells were observed against activation-induced death and growth
factor withdrawal-mediated death. The ability of CpG-ODN to protect T
cells from these forms of death was associated with the up-regulation
of antiapoptotic gene products including c-FLIP, bcl-xL, and, to some
extent, bcl-2. The effect of CpG-ODN on naive and memory T cells
required the expression of CD28 and was not dependent on the presence
of B lymphocytes, suggesting that other antigen-presenting
cells that respond to CpG-ODN, such as dendritic cells, may
provide antiapoptotic signals to T cells in an antigen-independent but
CD28/B7-dependent fashion. The present findings suggest that CpG-ODN
can disrupt normal T-cell homeostasis not by acting as a mitogen but by
preventing T-cell death that normally takes place as a mechanism to
maintain steady-state levels of T cells. These findings support a
potential means to expeditiously replenish and maintain the peripheral
lymphocyte population after severe immunodepletion such as that which
occurs in HIV-infected individuals and individuals undergoing
cytoablative therapies.
(Blood. 2002;100:2537-2545) Under normal conditions tight homeostatic control
ensures that the number of peripheral naive and antigen-primed T
lymphocytes remains steady.1-4 In mice the peripheral
pools of T cells are continuously replenished by 1 × 106
to 2 × 106 thymic T-cell emigrants each day regardless
of the existing peripheral T-cell population.5-7 The
thymic emigrants that survive in the periphery may continue to endure
throughout life, but their persistence is at the expense of other
resident T-cell inhabitants. The survival and expansion of T cells in
the periphery can also depend upon the state of activation that the T
cells have acquired. Naive T cells (CD44low,
CD62Lhigh, CD45RAhigh) require constant T-cell
receptor (TCR) "tickling"8 through the
interaction with major histocompatibility complex (MHC)
molecules presenting self-peptides.3,4,9 Moreover,
cytokines such as interleukin-7 (IL-7) and perhaps IL-4 play a pivotal
role in conveying survival signals to naive T cells.10-13
Adoptively transferred T cells are unable to expand significantly in an
already full T-cell compartment unless "space" is created by
reducing the size of the existing peripheral T-cell pool via
irradiation or antibody depletion. Under these conditions, adoptively
transferred naive T cells will survive and divide, sometimes
transiently, acquiring memory T-cell-like
characteristics.14,15
Antigen-experienced T cells (CD44high,
CD62Llow, CD45RO+) rapidly divide in response
to antigen-MHC complex stimulation, resulting in the generation of
effector T cells that disappear soon after the responsible pathogen is
eliminated and memory T cells, which survive for long periods of time
without further need of TCR tickling.1,8,16 In the
absence of antigen, memory T cells divide slowly in response to IL-15,
which is produced throughout various tissues.17
Yet IL-2 can play a dual role, serving as a survival factor for
resting T cells or as a proapoptotic factor during TCR
stimulation.18
In spite of the tight controls that seek to maintain constant T-cell
numbers throughout life, homeostasis is frequently broken. For example,
at the onset of an immune response during an acute infection, the
numbers of lymphocytes rapidly rise in both the circulation and the
lymphoid organs. The marked increase in T cells results not only from
the expansion of pathogen-specific lymphocytes, but also from the
bystander accumulation of nonspecific cells responding to high levels
of proinflammatory lymphokines or to pathogen-associated molecular
patterns that activate the innate immune system. For example, the
accumulation of both antigen-specific and bystander T cells occurs
after exposure to nonspecific stimuli such as type-I interferons or
bacterial lipopolysaccharide resulting from the prevention of
T-cell death and/or the enhancement of T-cell
proliferation.19,20
Synthetic oligodeoxynucleotides (ODN) containing unmethylated
cytosine-guanine (CpG) motifs that mimic bacterial DNA correspond to a
class of pathogen-associated molecular patterns that skew the
immune response to a Th1 phenotype function.21-23 As a
consequence, CpG-ODNs have been used as adjuvants to stimulate
cytotoxic T lymphocyte (CTL) responses to various
vaccines.24-27 We reported that CTL responses to peptide
immunization were significantly increased in a vaccination protocol
that included 9 daily injections of CpG-ODN.27 During the
course of these experiments we observed a dramatic increase in the
size of the spleen and the draining lymph nodes. The increase in
the size of the lymphoid organs induced by the repeated
administration of CpG-ODN did not require antigen and resulted in the
rise of T-cell numbers by approximately 4- to 5-fold. Furthermore, a
40-fold increase in the number of dendritic cells (DCs) in the spleen
of mice receiving the 9-day CpG therapy was observed.28
Here we describe how the repeated administration (9 daily 100 µg
injections) of CpG-ODN promotes the antigen-independent peripheral expansion of both memory and naive subsets of CD4+ and
CD8+ T cells in an already full T-cell compartment. The
effect of CpG-ODN does not appear to be mediated through the induction
of T-cell proliferation, as it occurs with B cells and other
antigen-presenting cells (APCs), but through the decrease in the rate
of T-cell death. Most interestingly, T-lymphocytes isolated from
CpG-ODN-treated mice were highly resistant to growth factor
withdrawal-induced apoptosis and activation-induced cell death (AICD).
The effects of CpG therapy in T cells appear to be mediated through an
increased expression of the antiapoptotic gene products c-FLIP and
bcl-xL. Experiments using gene knockout mice suggest that a
CD28/B7-dependent interaction of naive and memory T cells with
CpG-activated APCs other than B lymphocytes results in the expansion of
these T-cell pools. The present findings not only bear relevance for
the induction of potent and long-lasting immune responses but also may
be of use in other areas of immune therapy such as the repopulation of
T cells in deficient individuals or in other circumstances where T-cell
apoptosis plays a critical role in pathogenesis.
Mice and immunizations
Apoptotic assays
For induction of growth factor deprivation-induced death, naive CD62L+, CD4+, or CD8+ T cells were purified using T-Cell Separation Columns (R&D Systems) and were resuspended at a density of 2 × 105 cells/mL for the induction of apoptosis. Apoptosis was induced by serum and cytokine withdrawal for the indicated time periods and quantitated by flow cytometry annexin-V as described above. In one experiment (Figure 4C), the purified naive T cells were labeled with the fluorescent probe 5,6-carboxyfluorescein diacetate, succimidyl ester (CFSE; Molecular Probes, Eugene, OR). Briefly, freshly purified T cells from Neg-ODN-treated mice were washed once and resuspended at 2 × 107 cells/mL in serum-free RPMI 1640 medium. An equal volume of 2 µM CFSE was added to the cells, and they were mixed gently and incubated at 37°C for 10 minutes. After the incubation period, an equal volume of fetal bovine serum (FBS) was added to quench the reaction, and the cells were washed 2 times in medium containing 10% FBS. CFSE-labeled T cells were then mixed with equal numbers of unlabeled naive T cells from CpG-ODN-treated mice in order to determine the numbers of apoptotic (annexin-V+) cells from each subpopulation at various time points. Western blots For Western blot analyses, about 30 µg whole cell extract protein was separated by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), blotted onto a Hybond C nitrocellulose membrane, and blocked with 2% bovine serum albumin in Tris-buffered saline (TBS)/Tween 20 (0.05% Tween 20). After washing with TBS/Tween 20, blots were incubated with protein A-horseradish peroxidase (1/10 000) for 1 hour at room temperature, washed again, and developed with the ECL Western Blotting Detection kit (Amersham Pharmacia Biotech, Piscataway, NJ). All antibodies used for Western blot analysis were purchased from Santa Cruz Biotechnology, Santa Cruz, CA.RNase protection assays Total RNA was extracted from lymph node (LN) or splenic cells using the RNeasy minikit (Qiagen, Valencia, CA). The RNA was redissolved in RNase-free water, and yield was estimated by spectrophotometry. RNase protection assays (RPAs) were performed using RiboQuant from BD PharMingen according to the manufacturer's protocol. The multiprobe template sets were the mouse APO-3 and a custom design consisting of the mouse APO-2; however, bf1 was replaced for a FLICE inhibitory protein (FLIP) probe. The templates were used to synthesize the 32[p]-UTP-labeled probes (3000 Ci/mmol [111 000 GBq/mmol], 10 mCi/mL [370 MBq/mL]; NEN Life Science Products, Boston, MA) in the presence of a deoxynucleotide pool using a T7 RNA polymerase (BD PharMingen). Hybridization with 10 µg RNA was performed for 12 to 14 hours at 56°C, and the products were digested with RNase A and T1 mixture. The samples were treated by proteinase K in proteinase K buffer with yeast tRNA and then extracted with phenol and chloroform-isoamyl alcohol (50:1) and precipitated in the presence of ammonium acetate. The samples were loaded on acrylamide-urea gel and run at 40 W with 0.5 × Tris-borate-EDTA (ethylenediaminetetraacetic acid) electrophoresis buffer for 2 hours. The gel was adsorbed to filter paper, vacuum dried, and then exposed on film (X-AR; Kodak, Rochester, NY) with intensifying screens at 70°C.
Cytofluorometric analyses Numbers of cells from lymphoid organs were determined by cytofluorography using fluoresceinated antibodies specific for these cell populations. For the analysis of cell surface expression, 1 × 106 cells were stained with monoclonal antibody (mAb) for 45 minutes at 4°C in 50 µL of PBS containing 0.1% sodium azide and 2% fetal calf serum (FCS). Cells were then washed and analyzed for CD8, CD3, CD4, CD11c, CD25, CD44, CD45RA, and CD69 expression on a Becton Dickinson FACScan (San Jose, CA). The mAbs used were purchased from PharMingen. For studies involving CFSE staining, naive T cells were stained with CFSE (Molecular Probes). In brief, cells were resuspended in PBS at 1 × 107/mL. CFSE was added to the cell suspension at a final concentration of 10 µM and incubated for 10 minutes at 37°C. Cells were washed 3 times in ice-cold RPMI 1640 with 20% FCS, recounted, and resuspended at 1.5 × 107/mL.Evaluation of in vivo cell expansion Normal C57BL/6, CD28 /, or µMT/
mice received 9 daily injections of 100 µg CpG-ODN or Neg-ODN. One
day after the last injection, the draining axillary lymph
nodes and spleens were harvested and pooled for each group. The total
numbers of live cells were determined via trypan blue exclusion of
viable cells by counting the cells in a hemocytometer. The numbers of
naive (CD44low) and memory (CD44high)
CD4+/CD3+ and CD8+/CD3+
T cells, activated (CD80high) CD19+ B cells,
and activated (CD80high) CD19-CD11c+ DCs for
each treatment group was determined by 3-color flow cytometry. The
total fold increase for each cell type/subset was calculated by
multiplying the percentage of the corresponding group by the total
number of live cells obtained per organ. The error bars in
Figures 8 and 9 represent the standard error of the means obtained from
3 separate experiments.
CpG-ODN induces a systemic but transient expansion of T lymphocytes in the absence of antigen We first observed that the repeated daily subcutaneous injections of 100 µg of CpG-ODN into the nape of the neck resulted in a significant increase not only in the size of the corresponding draining axillary lymph nodes, but also in the size of the spleens (Figure 1). Control synthetic ODN not containing a CpG motif (Neg-ODN) failed to induce splenomegaly, lymphoadenopathy, or to increase the number of cells in these organs. In CpG-ODN-treated mice the numbers of both CD4+ and CD8+ T lymphocytes in spleens were significantly increased as compared to the control (Neg-ODN) mice (Table 1). Interestingly, both the naive (CD44low) and the memory/activated (CD44high) T-cell subsets were increased approximately 3- to 4-fold. Similar effects were observed in the cell numbers obtained from the draining lymph nodes (data not shown). In addition to the effects of CpG-ODN on T lymphocytes, there was an average 12-fold increase in the number of B cells, 13-fold increase in NK cells, and a 15- to 40-fold increase in the number of CD11c+ DCs and CD11b+ macrophages obtained from CpG-treated mice as compared to PBS-treated mice (data not shown). The effects of CpG-ODN were transient since the total numbers of T cells were restored to normal numbers approximately 20 days after the last CpG-ODN injection (data not presented). The decrease in T-cell numbers during this phase paralleled with a decrease in B cells, DCs, and macrophages. These results indicate that the repeated administration of CpG-ODN results in a dramatic antigen-independent increase in the overall number of lymphocytes as well as accessory cells, with a systemic yet transient lymphoadenopathy and splenomegaly ensuing.
Lack of mitogenic effect of CpG-ODN on T lymphocytes The significant increase in T-cell numbers in CpG-ODN-treated mice suggested that this compound could be functioning as a typical mitogen such as concanavalin-A, inducing the proliferation of these cells in an antigen nonspecific manner. To investigate whether CpG-ODN induced the expansion of T cells via increased proliferation, we quantitated the numbers of dividing T lymphocytes via cell-cycle analysis using propidium iodide (PI) DNA staining. Data in Figure 2 indicate that the number of CD4 and CD8 T cells entering cell cycle (high content of DNA) slightly increased (about 16%) in the CpG-ODN-treated animals as compared to the Neg-ODN-treated mice. Yet, consistent with the knowledge that CpG-ODNs function as mitogens for B lymphocytes,29 the number of these cells entering the cell cycle more than doubled in the CpG-ODN-treated mice as compared to the controls (Figure 2). Similar results were obtained when the proportion of dividing T cells was determined by bromodeoxyuridine (BrdU) incorporation into DNA, which was measured by flow cytometry by double-staining permeabilized CD3+ T cells with an anti-BrdU antibody. In these experiments we observed a small increase (7%) in the number of dividing T cells in the CpG-ODN-treated mice as compared to the untreated controls after receiving 4 daily injections of CpG-ODN. In addition, after 9 injections of CpG-ODN, there was no further increase in the number of BrdU-positive T cells (data not shown). Moreover, the effect of various concentrations of CpG-ODN in the induction of T-cell proliferation as measured by 3[H]-thymidine incorporation into DNA was evaluated both in the presence and absence of APCs. Under all conditions examined, CpG-ODN did not induce a significant proliferative response in either CD4+ or CD8+ T cells (data not presented). Collectively, these results indicate that CpG ODNs do not function as T-cell mitogens and that other mechanisms must be involved in the expansion of various T-cell subsets in mice receiving repeated doses of CpG-ODN.
CpG-ODNs induce the expansion of T cells in the peripheral lymphoid tissues The increase in the number of T cells could be the result of either a rise in the number of T lymphocytes emerging from the thymus or, alternatively, via the expansion of these cells occurring in the periphery. Thus, to ascertain the anatomical site of the CpG-ODN-induced increase in the T-cell numbers, we compared the effect of CpG therapy in the expansion of CD4+ and CD8+ T cells subsets in normal and thymectomized mice. The results in Figure 3 show that CpG therapy had similar effects on both normal and thymectomized mice, with respect to the increase in total T-cell numbers in their lymph nodes and spleens. In addition, CpG-ODN therapy affected both naive (CD44low) and memory (CD44high) CD4+ and CD8+ T cells (data not presented). These results suggest that CpG therapy augments T-cell numbers in the periphery even in the absence of thymic output and that both naive and antigen-experienced T cells are affected. However, it is possible that CpG-ODNs may also increase thymic output by altering positive/negative selection functions. Nevertheless, analysis for the various thymocyte subsets using flow cytometry showed that the numbers of the various thymic T-cell progenitor populations including double-negative, double-positive, or single-positive CD4 or CD8 cells were not altered in CpG-ODN-treated mice as compared to the PBS controls (data not shown).
CpG-ODN protects T cells against growth factor deprivation-induced cell death If the increase in T-lymphocyte numbers observed in CpG-ODN-treated mice is not the result of a stimulation of cell proliferation or an increase in thymic output, it would most likely be due to a decrease in the normal turnover of these cells. Thus, we proceeded to study whether CpG-ODN affects T-cell apoptosis, which is an important homeostatic mechanism that ensures that the total number of T lymphocytes remains relatively constant in the periphery. One mechanism that may help keep T-cell numbers in check is the competition for survival signals (growth factors and cell interactions with APCs) occurring between resident naive T cells and recent thymic emigrants. We tested the hypothesis that CpG-ODN may function in part by preventing growth factor deprivation-induced death in T cells. This possibility was evaluated by measuring the in vitro survival of purified naive T cells from normal and CpG-ODN-treated mice in the absence of growth factors (serum, lymphokines) and without APCs or other feeder cells. The results from these experiments showed an improved survival of both CD4+ and CD8+ T cells that were obtained from CpG-ODN-treated mice, as compared with T cells from control Neg-ODN-treated or untreated mice (Figures 4A,B). We considered the possibility that low numbers of contaminating non-T cells such as APCs in these cultures could be responsible for providing survival signals to the naive T cells from CpG-ODN-treated mice. Equal numbers of naive T cells from CpG-ODN-treated mice were mixed with CFSE-labeled naive T cells from Neg-ODN control mice, and cell numbers for both populations were evaluated at various time points. The results presented in Figure 4C demonstrate that in these mixed cultures, only the naive T cells from the CpG-ODN-treated mice survived in the absence of exogenous growth factors, indicating that the survival signals are not likely to be derived from contaminating APCs in these cultures. The overall data indicate that CpG therapy can confer protection against death resulting from growth factor withdrawal in both CD4+ and CD8+ T cells in the absence of APCs.
CpG-ODN prevents T cells from TCR-induced death The homeostatic control of naive and activated/memory T-cell numbers appears to be regulated differently. AICD is one of the mechanisms by which effector T-cell responses are down-regulated as a means to control the size of the peripheral T-cell pool.30,31 We thus proceeded to examine whether CpG therapy was affecting the size of the antigen-experienced CD44high T-cell population (Table 1) by rendering these T cells more resistant to AICD. To test this hypothesis, purified CD4+ and CD8+ T cells from untreated, CpG-ODN-treated, or Neg-ODN-treated mice were compared for their susceptibility to TCR-mediated AICD. For these experiments, the resting T cells were first rendered susceptible to AICD by TCR activation with plate-bound anti-CD3 and anti-CD28 antibodies (see "Materials and methods" for details). The recently activated T cells were then assayed for AICD mediated by TCR stimulation with various concentrations of plate-bound anti-CD3 antibodies. The results show that both CD4+ and CD8+ T cells obtained from CpG-treated mice were more resistant to AICD than the T cells obtained from untreated mice or Neg-ODN (Figure 5). However, the resistance to AICD was observed only at low to intermediate concentrations of anti-CD3 antibody, and the effects were more apparent in CD4+ T cells (Figure 5A) than in the CD8+ (Figure 5B) population. Resistance to AICD in T cells from CpG-ODN-treated mice remained evident even when the cells were obtained 5 days after the mice received the last CpG-ODN injection (data not presented). However, no significant protection against AICD was observed if the T cells were harvested 10 days after the final CpG-ODN injection (data not shown), indicating that although this effect persists for some time, the cells ultimately revert to the AICD-susceptible phenotype. The increased resistance to AICD in T cells from CpG-treated mice was not the result of an inhibition in the capacity of the T cells to respond to TCR activation, since these cells secreted similar levels of IL-2 upon anti-TCR stimulation as compared with the T cells from the untreated controls (data not shown). These results demonstrate that T cells are rendered more resistant against AICD and remain functionally active to TCR stimulation in response to CpG-ODN therapy.
CpG-ODN alters the expression of apoptotic-related genes in T cells Based on the data presented so far indicating that CpG-ODN is not mitogenic for T cells but prolongs T-cell survival under various conditions (growth factor withdrawal and AICD), we reasoned that CpG therapy may provoke the accumulation of peripheral T cells in vivo by inhibiting the apoptotic pathways responsible for maintaining T-cell homeostasis. We proceeded to study the effects of CpG therapy on the expression of apoptosis-related genes by analysis of RNA prepared from purified CD4+ and CD8+ T cells obtained from CpG-ODN-treated and Neg-ODN-treated mice. Upon treatment with CpG-ODN but not with Neg-ODN, the expression of the antiapoptotic genes bcl-w, bcl-xL, and c-FLIP (for cellular FLICE-inhibitory protein) was significantly up-regulated in both CD4+ and CD8+ T cells (Figure 6). In addition, the expression of the antiapoptotic gene bcl-2 also was found markedly up-regulated in CD4+ T cells derived from CpG-ODN-treated mice (Figure 6). However, the T-cell expression of various membrane-associated death-inducing molecules including Fas-L, Fas, and TNF-RI did not appear to differ between the CpG-ODN and Neg-ODN-treated mice. Paradoxically, CpG therapy appeared to produce a slight up-regulation of the proapoptotic genes bcl-xS and bak.
The presence of apoptotic-related proteins on purified CD4+
and CD8+ T cells derived from CpG-ODN-treated,
Neg-ODN-treated, and untreated mice was also examined by Western blot
analysis using antibodies specific for c-FLIP, bcl-x, bcl-2, bcl-3, and
Fas-L. The results presented in Figure 7
clearly show that CD4+ and CD8+ T cells from
CpG-ODN-treated mice expressed higher levels of the short form of
c-FLIP protein, c-FLIP(S), and at the same time the levels of the long
form of c-FLIP, c-FLIP(L), were diminished, as compared with the T
cells from control mice. The protein levels of bcl-xL, which like
c-FLIP has an antiapoptotic function for AICD, were found substantially
increased in both CD4+ and CD8+ T cells from
CpG-ODN-treated mice as compared with the controls. A small and less
dramatic increase of bcl-xS, which is correlated with proapoptotic
activity, was also observed in the T cells from CpG-ODN-treated mice.
Additionally, we detected only a small increase in the levels of bcl-2
and a moderate and most likely insignificant increase in the levels of
bcl-3 in T cells derived from CpG-ODN-treated mice as compared to the
controls. Taken together these data suggest that CpG-ODN can alter
T-cell homeostasis by rendering naive and antigen-experienced T cells
resistant to various apoptotic stimuli, which normally serve to
eliminate excess numbers of T cells.
Role of the CD28 costimulatory receptor in CpG-mediated T-cell expansion Up-regulation of antiapoptotic molecules such as bcl-xL and c-FLIP on T cells can occur as the result of CD28 costimulation.32,33 Since CpG-ODN are known to increase the expression of the CD28 ligands B7.1 and B7.2 on various APCs,34,35 we reasoned that the interaction of T cells with CpG-ODN-activated APCs involving CD28/B7 costimulation could be somehow involved in the expansion of T-lymphocyte pools resulting from CpG therapy. To assess the role of CD28 on the CpG-ODN-induced expansion of T cells, we compared the effects of CpG therapy in normal wild-type (WT) and CD28-deficient (CD28/) mice. As
previously noted, CpG therapy in normal, WT mice significantly increased the numbers of naive and antigen-experienced CD4+
and CD8+ T cells in the draining lymph nodes and spleens
(Figure 8). In addition, the numbers of
APCs (B lymphocytes and DCs) also were substantially increased as the
result of CpG therapy. In contrast, CpG therapy in
CD28/ mice did not result in the expansion of any of
the T-cell subsets, and the effects on APCs were less marked than those
observed in the WT mice (Figure 8). These results are strongly
indicative that the CpG-mediated expansion of T cells requires direct
cell-to-cell interaction with B7-expressing APCs, and this interaction
may involve CD28 stimulation.
B lymphocytes are not required for the CpG-ODN-induced expansion of T cells Based on the findings that CpG-ODN increases the expression of several costimulatory molecules including B7.1 and B7.2 on B cells and that this compound dramatically increases the number of B cells (6- to 11-fold increase, Figure 8 and Krieg et al29), we investigated the role of B cells in the CpG-mediated T-cell expansion. For this purpose we used the µMT/ mice, which have a
genetic alteration in the IgM transmembrane domain resulting in the
lack mature B lymphocytes. Again, the effects of CpG therapy in WT mice
showed a clear expansion of various subsets of T cells and APCs on both
lymph nodes and spleens (Figure 9).
Interestingly, CpG therapy in the µMT/ mice also
resulted in a significant expansion of all subsets of T cells (Figure
9). These effects were almost identical in the spleen, but the total
cell numbers on both CpG-ODN- and Neg-ODN-treated µMT/ mice were substantially lower on the lymph nodes
as compared to the WT mice. These results indicate that the
CpG-ODN-mediated expansion of CD8+ and CD4+ T
cells is not solely dependent on B lymphocytes, but it does not rule
out the possibility that these APCs may participate in the effects of
CpG-ODN in WT mice.
In the present study, we have shown that repeated administration of CpG-ODN leads to a disruption in T-cell homeostasis by significantly increasing the numbers of naive and antigen-experienced T lymphocytes in various lymphoid compartments. Although the effect was mostly apparent in the draining lymph nodes close to the CpG-ODN injection site, systemic effects were also observed in the spleen. Interestingly, we did not observe any alterations in T-cell homeostasis when mice were repetitively injected with purified bacterial DNA (9 daily doses of 100 µg/mice), which is rich in CpG motifs (data not presented). Thus, it is possible that the phosphorothioate groups in the CpG-ODN, which protect the ODN against degradation by nucleases, are critical for this activity. Similar requirements for the presence of phosphorothioate groups have been reported for the extramedullary hematopoiesis activity of CpG-ODN.36,37 The increase in T-cell numbers produced by CpG therapy does not appear
to result from an induction of cell proliferation, but from the
generation of an apoptotic resistance state that protects both
CD4+ and CD8+ T cells against growth
factor-deprivation cell death and AICD. The resistance to these
different modes of cell death correlated with an increase in the
expression of antiapoptotic molecules including c-FLIP, bcl-xL, and
bcl-2. We believe that CpG therapy does not directly induce these
changes on the T cells, but most likely the effect is mediated via
accessory cells such as APCs. It has been established that CpG-ODN
stimulate cell functions through Toll-like receptor-9 (TLR-9), which
has not been detected on T cells but is present on numerous types of
APCs such as DCs and B lymphocytes.38,39 In effect,
CpG-ODN activates both DCs and B cells to proliferate and become more
potent APCs by increasing the expression of adhesion molecules and
costimulatory ligands and inducing the secretion of numerous
cytokines.23,35,40-44 Moreover, our results with
CD28 At present we do not know all the exact mechanism(s) of how CpG-ODNs are able to enhance the expression of antiapoptotic genes in T cells, especially in the case of naive T cells and in the absence of antigen. It was recently reported that CpG-ODNs are able to inhibit apoptosis in DCs by up-regulating cellular inhibitors of apoptosis proteins, bcl-2 and bcl-xL.54 However, DCs, as well as other APCs, are capable of responding directly to CpG-ODN through the action of the TLR-9 receptor.38,39 Since TLR-9 does not appear to be expressed on T cells, the effect of CpG-ODN in increasing gene expression of antiapoptotic molecules must be through an accessory APC via direct cell-to-cell interactions and/or through soluble factors (cytokines). One possibility is that CpG induces the production of vast quantities of type I interferon (IFN) by various types of cells,7,55 but mostly in plasmocytoid DCs.56-58 It has been reported that type I IFN can induce survival signals through the activation of PI-3K and Akt and the sequential activation of nuclear factor (NF)-kB.59 Moreover, the induction in the production of IL-15 by these interferons will enhance the survival and expansion of memory CD8+ T cells,17 and the antiproliferative effect of type I IFN on lymphocytes60,61 could also have an effect in blocking cell death in those circumstances where cells need to progress through cell cycle to undergo apoptosis. Besides type I IFN, other cytokines that are induced by CpG-ODN such as IL-1, TNF-alpha, IL-6, IFN-gamma, and IL-1241-43 will likely influence the survival of T lymphocytes. Many of these proinflammatory cytokines are strong activators of NF-kB, resulting in the up-regulation of strong antiapoptotic factors such as c-FLIP and bcl-xL,62-64 both of which in our hands were induced in T cells by CpG therapy (Figure 7). As indicated by the present findings, the generation of survival signals for T cells by CpG therapy probably also derives from direct cell interactions with APCs. For instance, CpG up-regulates the expression of CD80 and CD86 in APCs,34,40 potentiating CD28 costimulation, which enhances T-cell survival by inducing expression of bcl-xL and c-FLIP.32,33 Some observations suggest that alterations of T-cell homeostasis by CpG-containing DNA may contribute to autoimmune diseases. Serum DNA from systemic lupus erythematosus (SLE) patients contains an enriched fraction of the CpG motifs, capable of activating monocytes.65 Immune complexes of anti-DNA antibodies with CpG-DNA may be effectively delivered to APCs through Fc receptors, potentiating their activation and cytokine production.66 Thus, it is possible that the release of CpG-DNA from necrotic cells could render autoreactive T cells more resistant to apoptosis, aggravating the chronic inflammatory response in autoimmune disorders. However, there is no experimental data to substantiate this possibility. Our findings suggest that besides their use as vaccine adjuvants, CpG-ODNs could have several additional clinical applications. For instance, CpG-ODN therapy could benefit HIV-infected individuals or patients receiving adoptive T-cell therapy by rendering these T cells more resistant to apoptosis, increasing their survival and effectiveness. If CpG-ODNs were to prevent T-cell death induced by other proapoptotic agents, we could also envision the use of CpG therapy in combination with conventional cytoablative treatments (radiation, chemotherapy) to diminish the induction of immunosuppression, which is often accompanied by these treatments. Providing support for this possibility are the observations that the expression of bcl-xL confers resistance to cell death induced by chemotherapeutic agents and irradiation.67,68
Submitted February 7, 2002; accepted May 3, 2002.
Prepublished online as Blood First Edition Paper, May 13, 2002; DOI 10.1182/blood-2002-02-0401.
Supported by grants R01CA80782, R01CA82677, and RR-00585 from the National Institutes of Health.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Esteban Celis, Department of Immunology, GU421A, Mayo Clinic, Rochester, MN 55905; e-mail: celis.esteban{at}mayo.edu.
1. Tanchot C, Rosado MM, Agenes F, Freitas AA, Rocha B. Lymphocyte homeostasis. Semin Immunol. 1997;9:331-337[CrossRef][Medline] [Order article via Infotrieve]. 2. Freitas AA, Rocha BB. Lymphocyte lifespans: homeostasis, selection and competition. Immunol Today. 1993;14:25-29[CrossRef][Medline] [Order article via Infotrieve]. 3. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:255-262[CrossRef][Medline] [Order article via Infotrieve]. 4. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 1999;11:173-181[CrossRef][Medline] [Order article via Infotrieve].
5.
Egerton M, Shortman K, Scollay R.
The kinetics of immature murine thymocyte development in vivo.
Int Immunol.
1990;2:501-507
6.
Berzins SP, Boyd RL, Miller JF.
The role of the thymus and recent thymic migrants in the maintenance of the adult peripheral lymphocyte pool.
J Exp Med.
1998;187:1839-1848 7. Gabor MJ, Scollay R, Godfrey DI. Thymic T cell export is not influenced by the peripheral T cell pool. Eur J Immunol. 1997;27:2986-2993[Medline] [Order article via Infotrieve]. 8. Bevan MJ, Goldrath AW. T-cell memory: you must remember this. Curr Biol. 2000;10:R338-R340[CrossRef][Medline] [Order article via Infotrieve]. 9. Freitas AA, Rocha B. Peripheral T cell survival. Curr Opin Immunol. 1999;11:152-156[CrossRef][Medline] [Order article via Infotrieve].
10.
Tan JT, Dudl E, LeRoy E, et al.
IL-7 is critical for homeostatic proliferation and survival of naive T cells.
Proc Natl Acad Sci U S A.
2001;98:8732-8737 11. Webb LM, Foxwell BM, Feldmann M. Interleukin-7 activates human naive CD4+ cells and primes for interleukin-4 production. Eur J Immunol. 1997;27:633-640[Medline] [Order article via Infotrieve]. 12. Hassan J, Reen DJ. IL-7 promotes the survival and maturation but not differentiation of human post-thymic CD4+ T cells. Eur J Immunol. 1998;28:3057-3065[CrossRef][Medline] [Order article via Infotrieve].
13.
Soares MV, Borthwick NJ, Maini MK, Janossy G, Salmon M, Akbar AN.
IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire.
J Immunol.
1998;161:5909-5917
14.
Murali-Krishna K, Ahmed R.
Cutting edge: naive T cells masquerading as memory cells.
J Immunol.
2000;165:1733-1737
15.
Goldrath AW, Bogatzki LY, Bevan MJ.
Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation.
J Exp Med.
2000;192:557-564 16. Tough DF, Sprent J. Lifespan of lymphocytes. Immunol Res. 1995;14:1-12[Medline] [Order article via Infotrieve]. 17. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8:591-599[CrossRef][Medline] [Order article via Infotrieve].
18.
Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P.
Control of homeostasis of CD8+ memory T cells by opposing cytokines.
Science.
2000;288:675-678
19.
Marrack P, Kappler J, Mitchell T.
Type I interferons keep activated T cells alive.
J Exp Med.
1999;189:521-530 20. Vella AT, McCormack JE, Linsley PS, Kappler JW, Marrack P. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity. 1995;2:261-270[CrossRef][Medline] [Order article via Infotrieve].
21.
Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV.
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
J Exp Med.
1997;186:1623-1631 22. Krieg AM. CpG DNA: a novel immunomodulator. Trends Microbiol. 1999;7:64-65[CrossRef][Medline] [Order article via Infotrieve]. 23. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999;73:329-368[Medline] [Order article via Infotrieve]. 24. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol. 1997;27:2340-2344[Medline] [Order article via Infotrieve]. 25. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998;6:23-27[CrossRef][Medline] [Order article via Infotrieve].
26.
Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM.
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.
Proc Natl Acad Sci U S A.
1997;94:10833-10837
27.
Davila E, Celis E.
Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
J Immunol.
2000;165:539-547 28. Grossmann ME, Davila E, Celis E. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001;24:237-241[Medline] [Order article via Infotrieve]. 29. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546-549[CrossRef][Medline] [Order article via Infotrieve]. 30. Kabelitz D, Janssen O. Antigen-induced death of T-lymphocytes. Front Biosci. 1997;2:d61-d77[Medline] [Order article via Infotrieve]. 31. Russell JH. Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol. 1995;7:382-388[CrossRef][Medline] [Order article via Infotrieve]. 32. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995;3:87-98[CrossRef][Medline] [Order article via Infotrieve]. 33. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28costimulated human T cells. Eur J Immunol. 2000;30:2765-2774[CrossRef][Medline] [Order article via Infotrieve]. 34. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998;28:2045-2054[CrossRef][Medline] [Order article via Infotrieve].
35.
Sun S, Zhang X, Tough DF, Sprent J.
Type I interferon-mediated stimulation of T cells by CpG DNA.
J Exp Med.
1998;188:2335-2342
36.
Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB, Wagner H.
Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis.
J Immunol.
1999;162:2368-2374
37.
Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H.
CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses.
J Immunol.
2000;165:1228-1235 38. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740-745[CrossRef][Medline] [Order article via Infotrieve]. 39. Wagner H. Toll meets bacterial CpG-DNA. Immunity. 2001;14:499-502[CrossRef][Medline] [Order article via Infotrieve].
40.
Hartmann G, Weiner GJ, Krieg AM.
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells.
Proc Natl Acad Sci U S A.
1999;96:9305-9310 41. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol. 1996;157:2116-2122[Abstract]. 42. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996;167:72-78[CrossRef][Medline] [Order article via Infotrieve].
43.
Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM.
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
Proc Natl Acad Sci U S A.
1996;93:2879-2883
44.
Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC.
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
J Immunol.
1998;161:3042-3049 45. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine. 1999;17:19-25[CrossRef][Medline] [Order article via Infotrieve]. 46. Mitchell TC, Hildeman D, Kedl RM, et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol. 2001;2:397-402[Medline] [Order article via Infotrieve].
47.
Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ.
Bcl-XL and Bcl-2 repress a common pathway of cell death.
J Exp Med.
1995;182:821-828 48. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195[CrossRef][Medline] [Order article via Infotrieve].
49.
Han DK, Chaudhary PM, Wright ME, et al.
MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death.
Proc Natl Acad Sci U S A.
1997;94:11333-11338
50.
Hu S, Vincenz C, Ni J, Gentz R, Dixit VM.
I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis.
J Biol Chem.
1997;272:17255-17257
51.
Inohara N, Koseki T, Hu Y, Chen S, Nunez G.
CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis.
Proc Natl Acad Sci U S A.
1997;94:10717-10722
52.
Scaffidi C, Schmitz I, Krammer PH, Peter ME.
The role of c-FLIP in modulation of CD95-induced apoptosis.
J Biol Chem.
1999;274:1541-1548
53.
Kirchhoff S, Muller WW, Krueger A, Schmitz I, Krammer PH.
TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity.
J Immunol.
2000;165:6293-6300
54.
Park Y, Lee SW, Sung YC.
Cutting edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway.
J Immunol.
2002;168:5-8 55. Sun S, Sprent J. Role of type I interferons in T cell activation induced by CpG DNA. Curr Top Microbiol Immunol. 2000;247:107-117[Medline] [Order article via Infotrieve].
56.
Siegal FP, Kadowaki N, Shodell M, et al.
The nature of the principal type 1 interferon-producing cells in human blood.
Science.
1999;284:1835-1837 57. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919-923[CrossRef][Medline] [Order article via Infotrieve]. 58. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001;31:2154-2163[CrossRef][Medline] [Order article via Infotrieve].
59.
Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM.
Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt.
J Biol Chem.
2001;276:13756-13761 60. Holan V, Nakamura S, Minowada J. Inhibitory versus stimulatory effects of natural human interferon-alpha on proliferation of lymphocyte subpopulations. Immunology. 1992;75:176-181[Medline] [Order article via Infotrieve]. 61. Petricoin EF III, Ito S, Williams BL, et al. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. Nature. 1997;390:629-632[CrossRef][Medline] [Order article via Infotrieve].
62.
Kreuz S, Siegmund D, Scheurich P, Wajant H.
NF-kappaB inducers up-regulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.
Mol Cell Biol.
2001;21:3964-3973
63.
Chen C, Edelstein LC, Gelinas C.
The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).
Mol Cell Biol.
2000;20:2687-2695
64.
Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J.
NF-kappaB signals induce the expression of c-FLIP.
Mol Cell Biol.
2001;21:5299-5305 65. Sato Y, Miyata M, Nishimaki T, Kochi H, Kasukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J Rheumatol. 1999;26:294-301[Medline] [Order article via Infotrieve]. 66. Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 2001;22:427-431[CrossRef][Medline] [Order article via Infotrieve].
67.
Minn AJ, Rudin CM, Boise LH, Thompson CB.
Expression of bcl-xL can confer a multidrug resistance phenotype.
Blood.
1995;86:1903-1910 68. Datta R, Manome Y, Taneja N, et al. Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995;6:363-370[Abstract].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. Zheng, N. Asprodites, A. H. Keene, P. Rodriguez, K. D. Brown, and E. Davila TLR9 engagement on CD4 T lymphocytes represses {gamma}-radiation-induced apoptosis through activation of checkpoint kinase response elements Blood, March 1, 2008; 111(5): 2704 - 2713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Celis Toll-like Receptor Ligands Energize Peptide Vaccines through Multiple Paths Cancer Res., September 1, 2007; 67(17): 7945 - 7947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse Blood, May 15, 2007; 109(10): 4564 - 4574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nava-Parada, G. Forni, K. L. Knutson, L. R. Pease, and E. Celis Peptide Vaccine Given with a Toll-Like Receptor Agonist Is Effective for the Treatment and Prevention of Spontaneous Breast Tumors Cancer Res., February 1, 2007; 67(3): 1326 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Teleshova, J. Kenney, G. Van Nest, J. Marshall, J. D. Lifson, I. Sivin, J. Dufour, R. Bohm, A. Gettie, and M. Robbiani Local and Systemic Effects of Intranodally Injected CpG-C Immunostimulatory-Oligodeoxyribonucleotides in Macaques J. Immunol., December 15, 2006; 177(12): 8531 - 8541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Jiang, A. Patrick, R. B. Moss, and K. L. Rosenthal CD8+ T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligodeoxynucleotides J. Virol., January 1, 2005; 79(1): 393 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hiraoka, S. Yamamoto, S. Otsuru, S. Nakai, K. Tamai, R. Morishita, T. Ogihara, and Y. Kaneda Enhanced Tumor-Specific Long-Term Immunity of Hemaggluttinating Virus of Japan-Mediated Dendritic Cell-Tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides J. Immunol., October 1, 2004; 173(7): 4297 - 4307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Petrovas, Y. M. Mueller, I. D. Dimitriou, P. M. Bojczuk, K. C. Mounzer, J. Witek, J. D. Altman, and P. D. Katsikis HIV-Specific CD8+ T Cells Exhibit Markedly Reduced Levels of Bcl-2 and Bcl-xL J. Immunol., April 1, 2004; 172(7): 4444 - 4453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Baines and E. Celis Immune-mediated Tumor Regression Induced by CpG-containing Oligodeoxynucleotides Clin. Cancer Res., July 1, 2003; 9(7): 2693 - 2700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Davila, R. Kennedy, and E. Celis Generation of Antitumor Immunity by Cytotoxic T Lymphocyte Epitope Peptide Vaccination, CpG-oligodeoxynucleotide Adjuvant, and CTLA-4 Blockade Cancer Res., June 15, 2003; 63(12): 3281 - 3288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Kandimalla, L. Bhagat, D. Wang, D. Yu, F.-G. Zhu, J. Tang, H. Wang, P. Huang, R. Zhang, and S. Agrawal Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles Nucleic Acids Res., May 1, 2003; 31(9): 2393 - 2400. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
), CpG-ODN-treated
(
), or Neg-ODN-treated (
) mice one day after the last ODN
injection. T cells were purified from splenocytes and lymph nodes, and
the naive T cells were further selected using anti-CD62L antibody
coated magnetic beads. Purified naive CD4+ (A) or
CD8+ (B) T cells were cultured separately in the absence of
serum and exogenous cytokines for up to 12 hours. As a positive
control, naive T cells from untreated mice were cultured in the
presence of 5% FCS and 25 IU IL-2/mL (
). The percent apoptotic
cells were evaluated 6 and 12 hours after the initiation of the
experiment by flow cytometry using annexin-V staining. (C) Purified
naive T cells from Neg-ODN-treated mice were first labeled with CFSE
and then mixed with an equal number of naive T cells (unlabeled) from
CpG-ODN-treated mice. The cell mixture was placed in culture in medium
lacking growth factors, and the numbers of viable CFSE-positive and
CFSE-negative cells were estimated at various time points as described
above. Error bars represent the standard errors of the means obtained
from 3 different mice per group.
